Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Strs Ohio

Strs Ohio trimmed its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Rating) by 39.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,400 shares of the biopharmaceutical company’s stock after selling 40,100 shares during the period. Strs Ohio owned 0.06% of Catalyst Pharmaceuticals worth $800,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in CPRX. Bank of New York Mellon Corp lifted its holdings in Catalyst Pharmaceuticals by 16.7% during the first quarter. Bank of New York Mellon Corp now owns 569,542 shares of the biopharmaceutical company’s stock valued at $4,722,000 after purchasing an additional 81,325 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in Catalyst Pharmaceuticals by 39.7% during the first quarter. MetLife Investment Management LLC now owns 49,347 shares of the biopharmaceutical company’s stock valued at $409,000 after purchasing an additional 14,017 shares in the last quarter. APG Asset Management N.V. purchased a new position in Catalyst Pharmaceuticals during the first quarter valued at $1,093,000. Dimensional Fund Advisors LP lifted its holdings in Catalyst Pharmaceuticals by 12.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,145,254 shares of the biopharmaceutical company’s stock valued at $17,784,000 after purchasing an additional 241,686 shares in the last quarter. Finally, Sei Investments Co. lifted its holdings in Catalyst Pharmaceuticals by 70.1% during the first quarter. Sei Investments Co. now owns 295,714 shares of the biopharmaceutical company’s stock valued at $2,445,000 after purchasing an additional 121,870 shares in the last quarter. 86.66% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $21.05 on Monday. The firm’s 50-day moving average is $17.38 and its two-hundred day moving average is $13.99. Catalyst Pharmaceuticals, Inc. has a 12 month low of $5.24 and a 12 month high of $22.11. The company has a market capitalization of $2.19 billion, a PE ratio of 34.51 and a beta of 1.19.

Catalyst Pharmaceuticals (NASDAQ:CPRXGet Rating) last announced its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Catalyst Pharmaceuticals had a net margin of 34.90% and a return on equity of 28.53%. The business had revenue of $57.24 million during the quarter, compared to analysts’ expectations of $53.80 million. Sell-side analysts forecast that Catalyst Pharmaceuticals, Inc. will post 0.73 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on CPRX shares. Piper Sandler raised their price target on shares of Catalyst Pharmaceuticals from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 20th. Truist Financial raised their price target on shares of Catalyst Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, December 21st. StockNews.com downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 9th. Finally, HC Wainwright raised their price target on shares of Catalyst Pharmaceuticals from $18.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, December 21st. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.38.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, CFO Alicia Grande sold 60,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $15.77, for a total transaction of $946,200.00. Following the completion of the sale, the chief financial officer now directly owns 147,442 shares in the company, valued at $2,325,160.34. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Patrick J. Mcenany sold 350,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $15.62, for a total value of $5,467,000.00. Following the completion of the transaction, the chief executive officer now owns 3,902,606 shares in the company, valued at $60,958,705.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Alicia Grande sold 60,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $15.77, for a total transaction of $946,200.00. Following the completion of the transaction, the chief financial officer now owns 147,442 shares of the company’s stock, valued at approximately $2,325,160.34. The disclosure for this sale can be found here. Insiders sold a total of 942,703 shares of company stock worth $14,867,756 over the last three months. Insiders own 14.10% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

(Get Rating)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

See Also

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Rating).

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.